Loading...
Header Logo
Keywords
Last Name
Institution

Kathleen Moore

TitleProf,Asoc
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentObstetrics and Gynecology
Address800 NE 10th St
Oklahoma City OK 73104-0001
Phone405/271-8707
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    5U10CA180798-05     (MANNEL, ROBERT S)Apr 24, 2014 - Feb 28, 2019
    NIH
    Lead Academic Participating Site for the Development and Conduct of NCTN Trials
    Role: Co-Investigator

    3U10CA180798-05S1     (MANNEL, ROBERT S)Apr 24, 2014 - Feb 28, 2019
    NIH
    Lead Academic Participating Site for the Development and Conduct of NCTN Trials
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Essel KG, Moore KN. Niraparib for the treatment of ovarian cancer. Expert Rev Anticancer Ther. 2018 Jun 17. PMID: 29911447.
      View in: PubMed
    2. Grisham R, Moore KN, Gordon MS, Harb W, Cody GR, Halpenny DF, Makker V, Aghajanian C. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. Clin Cancer Res. 2018 May 29. PMID: 29844129.
      View in: PubMed
    3. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 May 24. PMID: 29804638.
      View in: PubMed
    4. Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM. Clinical trial methodology in rare gynecologic tumor research: Strategies for success. Gynecol Oncol. 2018 Jun; 149(3):605-611. PMID: 29699802.
      View in: PubMed
    5. Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 Apr 11. PMID: 29643063.
      View in: PubMed
    6. Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res. 2018 Apr 10. PMID: 29636360.
      View in: PubMed
    7. Dockery LE, Motwani A, Ding K, Doescher M, Dvorak JD, Moore KN, Holman LL. Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough. Gynecol Oncol. 2018 Apr; 149(1):89-92. PMID: 29605056.
      View in: PubMed
    8. Buechel M, McGinnis A, Vesely SK, Wade KS, Moore KN, Gunderson CC. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes. Gynecol Oncol. 2018 Apr; 149(1):28-32. PMID: 29605046.
      View in: PubMed
    9. Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 Mar 28. PMID: 29593098.
      View in: PubMed
    10. Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 Jul 01; 425:174-182. PMID: 29574275.
      View in: PubMed
    11. Castellano T, Moore KN, Holman LL. An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers. Clin Ther. 2018 Mar; 40(3):372-388. PMID: 29530456.
      View in: PubMed
    12. Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018 Feb 09. PMID: 29424243.
      View in: PubMed
    13. Moore KN, Mirza MR, Matulonis UA. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 Apr; 149(1):214-220. PMID: 29397193.
      View in: PubMed
    14. Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR. Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open. 2018; 3(2):e000291. PMID: 29464110.
      View in: PubMed
    15. Gunderson CC, Matulonis U, Moore KN. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018 Mar; 148(3):591-600. PMID: 29395304.
      View in: PubMed
    16. Hagemann AR, McCourt CK, Varaday SS, Moore KN. Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery. Gynecol Oncol. 2018 Mar; 148(3):601-608. PMID: 29329881.
      View in: PubMed
    17. Moore K, Zhang ZY, Agarwal S, Burris H, Patel MR, Kansra V. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 Mar; 81(3):497-503. PMID: 29322231.
      View in: PubMed
    18. Ricci S, Tergas AI, Long Roche K, Fairbairn MG, Levinson KL, Dowdy SC, Bristow RE, Lopez M, Slaughter K, Moore K, Fader AN. Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. Gynecol Oncol Rep. 2017 Nov; 22:100-104. PMID: 29201989.
      View in: PubMed
    19. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan; 14(2):123-136. PMID: 29098867.
      View in: PubMed
    20. Dockery LE, Tew WP, Ding K, Moore KN. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513. PMID: 29037805.
      View in: PubMed
    21. Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol. 2018 01; 218(1):109.e1-109.e11. PMID: 29037481.
      View in: PubMed
    22. Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401. PMID: 28935272.
      View in: PubMed
    23. Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407. PMID: 28843653.
      View in: PubMed
    24. Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290. PMID: 28802766.
      View in: PubMed
    25. Greenwade MM, Moore KN, Gillen JM, Ding K, Rowland MR, Crim AK, Kleis B, Gunderson CC. Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017 09; 146(3):465-469. PMID: 28689668.
      View in: PubMed
    26. Danala G, Thai T, Gunderson CC, Moxley KM, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. Acad Radiol. 2017 Oct; 24(10):1233-1239. PMID: 28554551.
      View in: PubMed
    27. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 May 22; 8:14634. PMID: 28530221.
      View in: PubMed
    28. Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecol Oncol. 2017 07; 146(1):101-108. PMID: 28527672.
      View in: PubMed
    29. Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145. PMID: 28483269.
      View in: PubMed
    30. Bishop EA, Java JJ, Moore KN, Walker JL. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer. 2017 05; 27(4):730-737. PMID: 28399028.
      View in: PubMed
    31. Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087. PMID: 28440955.
      View in: PubMed
    32. Ahsen ME, Boren TP, Singh NK, Misganaw B, Mutch DG, Moore KN, Backes FJ, McCourt CK, Lea JS, Miller DS, White MA, Vidyasagar M. Sparse feature selection for classification and prediction of metastasis in endometrial cancer. BMC Genomics. 2017 03 27; 18(Suppl 3):233. PMID: 28361685.
      View in: PubMed
    33. Wang Y, Qiu Y, Thai T, Moore K, Liu H, Zheng B. A two-step convolutional neural network based computer-aided detection scheme for automatically segmenting adipose tissue volume depicting on CT images. Comput Methods Programs Biomed. 2017 Jun; 144:97-104. PMID: 28495009.
      View in: PubMed
    34. Gillen J, Gunderson C, Greenwade M, Rowland M, Ruskin R, Ding K, Crim A, Walter A, White E, Moore K. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36. PMID: 28087143.
      View in: PubMed
    35. Moore K, Brewer MA. Endometrial Cancer: Is This a New Disease? Am Soc Clin Oncol Educ Book. 2017; 37:435-442. PMID: 28561715.
      View in: PubMed
    36. Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, Erickson BK, Leath CA, Diaz Moore ES, Cohen JG, Walsh CS. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol. 2017 Feb; 144(2):274-278. PMID: 27979319.
      View in: PubMed
    37. Thomas ED, Nugent EK, MacAllister MC, Moxley KM, Landrum L, L Walker J, McMeekin DS, Mannel RS, McGwin G, Moore KN. Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial. Gynecol Oncol. 2017 Jan; 144(1):193-199. PMID: 27836205.
      View in: PubMed
    38. Wang Y, Qiu Y, Thai T, Moore K, Liu H, Zheng B. Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. BMC Med Imaging. 2016 08 31; 16(1):52. PMID: 27581075.
      View in: PubMed
    39. Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016 Nov; 143(2):294-301. PMID: 27542967.
      View in: PubMed
    40. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 10; 143(1):3-15. PMID: 27650684.
      View in: PubMed
    41. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Oct 01; 34(28):3460-73. PMID: 27502591.
      View in: PubMed
    42. Atri M, Zhang Z, Dehdashti F, Lee SI, Ali S, Marques H, Koh WJ, Moore K, Landrum L, Kim JW, DiSilvestro P, Eisenhauer E, Schnell F, Gold M. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9. PMID: 27178725; PMCID: PMC4993667 [Available on 09/01/17].
    43. Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45. PMID: 27423378.
      View in: PubMed
    44. Gunderson CC, Walter AC, Ruskin R, Ding K, Moore KN. Post-intensive care unit syndrome in gynecologic oncology patients. Support Care Cancer. 2016 11; 24(11):4627-32. PMID: 27306212.
      View in: PubMed
    45. Moore KN, Monk BJ. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63. PMID: 27256873; PMCID: PMC4978548 [Available on 08/01/17].
    46. Moore K, Stone R, Walter A. Society of Gynecologic Oncology 2016 Annual Meeting: Highlights and context. Gynecol Oncol. 2016 06; 141(3):416-420. PMID: 27138457.
      View in: PubMed
    47. Wang Y, Thai T, Moore K, Ding K, McMeekin S, Liu H, Zheng B. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients. Oncol Lett. 2016 Jul; 12(1):680-686. PMID: 27347200.
      View in: PubMed
    48. Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, McMeekin DS, Moore KM. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016 08; 142(2):225-30. PMID: 27208536.
      View in: PubMed
    49. Gunderson CC, Rowland MR, Wright DL, Andrade KL, Mannel RS, McMeekin DS, Moore KN. Initiation of a formalized precision medicine program in gynecologic oncology. Gynecol Oncol. 2016 Apr; 141(1):24-8. PMID: 27016225.
      View in: PubMed
    50. Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263. PMID: 26968641.
      View in: PubMed
    51. Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016 06; 34(3):290-9. PMID: 26961907.
      View in: PubMed
    52. Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BKR, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ESM, Chan EM, Bendell JC. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer. 2016 Mar; 56:1-9. PMID: 26798966.
      View in: PubMed
    53. Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, Soslow RA, Leitao MM. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4. PMID: 26509849; PMCID: PMC4891809 [Available on 01/01/17].
    54. Qiu Y, Tan M, McMeekin S, Thai T, Ding K, Moore K, Liu H, Zheng B. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol. 2016 Sep; 57(9):1149-55. PMID: 26663390.
      View in: PubMed
    55. Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, Tenney ME, Rose PG, Fracasso PM. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):204-9. PMID: 26616225; PMCID: PMC4724478.
    56. Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):161-6. PMID: 26586415.
      View in: PubMed
    57. Tan M, Li Z, Qiu Y, McMeekin SD, Thai TC, Ding K, Moore KN, Liu H, Zheng B. A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration. IEEE Trans Med Imaging. 2016 Jan; 35(1):316-25. PMID: 26336119.
      View in: PubMed
    58. Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart AC, O'Bryant C, Moore KN. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84. PMID: 26281907.
      View in: PubMed
    59. Gunderson CC, Moore KN. BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Expert Rev Mol Diagn. 2015; 15(9):1111-6. PMID: 26292709.
      View in: PubMed
    60. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015 Sep; 138(3):513-8. PMID: 26171911; PMCID: PMC4692151.
    61. Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):614-9. PMID: 26144601; PMCID: PMC4556563.
    62. Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH. Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets. Int J Gynecol Cancer. 2015 Jul; 25(6):1015-22. PMID: 26098089; PMCID: PMC4477286.
    63. Moore KN, Rowland MR. Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better? J Clin Oncol. 2015 Jul 01; 33(19):2125-8. PMID: 25987695.
      View in: PubMed
    64. McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40. PMID: 25958319; PMCID: PMC4643744.
    65. Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9. PMID: 25838164; PMCID: PMC4484273.
    66. Landrum LM, Blank S, Chen LM, Duska L, Bae-Jump V, Lee PS, Levine L, McCourt C, Moore KN, Urban RR. Comprehensive care in gynecologic oncology: The importance of palliative care. Gynecol Oncol. 2015 May; 137(2):193-202. PMID: 25749723.
      View in: PubMed
    67. Walter AC, Gunderson CC, Vesely SK, Algan O, Sughrue M, Slaughter KN, Moore KN. Central nervous system metastasis in gynecologic cancer: symptom management, prognosis and palliative management strategies. Gynecol Oncol. 2015 Mar; 136(3):472-7. PMID: 25752572.
      View in: PubMed
    68. Bendell JC, Patel MR, Infante JR, Kurkjian CD, Jones SF, Pant S, Burris HA, Moreno O, Esquibel V, Levin W, Moore KN. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 01; 121(7):1056-63. PMID: 25411085.
      View in: PubMed
    69. Slaughter KN, Moore KN, Mannel RS. Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials. Curr Oncol Rep. 2014 Nov; 16(11):412. PMID: 25292279.
      View in: PubMed
    70. Chuang L, Moore KN, Creasman WT, Goodman A, Henriquez Cooper H, Price FV, Conner MG, Gupta V, Gallion HH, Husseinzadeh N, Duarte J, Vu QH, Sanchez JA, Kanis MJ. Teaching gynecologic oncology in Low resource settings: a collaboration of health volunteers overseas and the society of gynecologic oncology. Gynecol Oncol. 2014 Dec; 135(3):580-2. PMID: 25308928.
      View in: PubMed
    71. Mannel RS, Moore K. Research: An event or an environment? Gynecol Oncol. 2014 Sep; 134(3):441-2. PMID: 25199577.
      View in: PubMed
    72. Moore K, Infante JR, Cotreau MM, Wilson L, Strahs AL, Vargo DL, Chadha M. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2014 Jul; 3(4):284-9. PMID: 27128834.
      View in: PubMed
    73. Gunderson CC, Java J, Moore KN, Walker JL. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014 Apr; 133(1):23-7. PMID: 24680587.
      View in: PubMed
    74. Perry LJ, Mathews C, Nugent E, Farrell R, Zorn K, Moore K. Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation. Int J Gynecol Cancer. 2014 Mar; 24(3):564-9. PMID: 24552890.
      View in: PubMed
    75. Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, Walker JL, McMeekin DS. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4. PMID: 24219982.
      View in: PubMed
    76. Gunderson CC, Nugent EK, Yunker AC, Rocconi RP, Graybill WS, Erickson BK, Moore KN. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. J Low Genit Tract Dis. 2013 Oct; 17(4):409-13. PMID: 23609592.
      View in: PubMed
    77. Gunderson CC, Farrell R, Dinh BC, Thomas ED, Vesely SK, Lauer JK, Kao L, Chopra S, McMeekin DS, Moore KN. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful? Gynecol Oncol. 2013 Sep; 130(3):411-5. PMID: 23791827.
      View in: PubMed
    78. Pant S, Burris HA, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93. PMID: 23525756; PMCID: PMC3913846.
    79. Simpkins F, Papadia A, Kunos C, Michener C, Frasure H, AbuShahin F, Mariani A, Bakkum-Gamez JN, Landrum L, Moore K, Thomas SG, Windhorn A, Rose PG. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion. Int J Gynecol Cancer. 2013 Jan; 23(1):98-104. PMID: 23221731.
      View in: PubMed
    80. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7. PMID: 23262204.
      View in: PubMed
    81. Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61. PMID: 22960004.
      View in: PubMed
    82. Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Apr; 121(1):118-21. PMID: 21159366.
      View in: PubMed
    83. Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, Gallion HH. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer. 2010 Dec 01; 116(23):5407-14. PMID: 20737572.
      View in: PubMed
    84. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2010 Jan; 116(1):10-4. PMID: 19875158.
      View in: PubMed
    85. Moore KN, Frank SG, Alward EK, Landrum LM, Myers TK, Walker JL, Gold MA, McMeekin DS, Vesely SK, Mannel RS. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80. PMID: 19235786.
      View in: PubMed
    86. Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, Walker JL, McMeekin DS, Mannel RS. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9. PMID: 18495221.
      View in: PubMed
    87. Moore KN, Bannon RJ, Lanneau GS, Zuna RE, Walker JL, Gold MA. Cervical dysplasia among women over 35 years of age. Am J Obstet Gynecol. 2008 Nov; 199(5):471.e1-5. PMID: 18486088.
      View in: PubMed
    88. Moore KN, Gold MA, McMeekin DS, Walker JL, Rutledge T, Zorn KK. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71. PMID: 18191994.
      View in: PubMed
    89. Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass IA, Rose PG, Leath CA, Rutledge T, Blankenship D, Gold MA. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403. PMID: 17997146.
      View in: PubMed
    90. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007 Aug; 197(2):141.e1-6. PMID: 17689626.
      View in: PubMed
    91. Moore KN, Lanneau GS, Smith C, Lanneau M, Walker JL, Gold MA, Scott McMeekin D. Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. Gynecol Oncol. 2007 Sep; 106(3):572-8. PMID: 17618678.
      View in: PubMed
    92. Lanneau GS, Skaggs V, Moore K, Stowell S, Zuna R, Gold MA. A LEEP cervical conization is rarely indicated for a two-step discrepancy. J Low Genit Tract Dis. 2007 Jul; 11(3):134-7. PMID: 17596756.
      View in: PubMed
    93. Moore KN, Gold MA, McMeekin DS, Zorn KK. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol. 2007 Sep; 106(3):498-501. PMID: 17561235.
      View in: PubMed
    94. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May; 105(2):299-303. PMID: 17303230.
      View in: PubMed
    95. Chi DS, Abu-Rustum NR, Sonoda Y, Ivy J, Rhee E, Moore K, Levine DA, Barakat RR. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005 May; 192(5):1614-9. PMID: 15902166.
      View in: PubMed
    96. Abu-Rustum NR, Gemignani ML, Moore K, Sonoda Y, Venkatraman E, Brown C, Poynor E, Chi DS, Barakat RR. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol. 2003 Nov; 91(2):402-9. PMID: 14599873.
      View in: PubMed
    Moore's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _